Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4%

Posted by Erica Schwartz on Apr 26th, 2024

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) were down 4% during trading on Wednesday . The company traded as low as $12.36 and last traded at $12.62. Approximately 28,642 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 45,720 shares. The stock had previously closed at $13.14.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research note on Wednesday, February 28th.

Check Out Our Latest Research Report on GLSI

Greenwich LifeSciences Stock Up 6.3 %

The company has a 50-day moving average price of $15.54 and a 200-day moving average price of $11.84. The firm has a market capitalization of $168.96 million, a price-to-earnings ratio of -18.74 and a beta of 1.38.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last released its earnings results on Monday, April 15th. The company reported ($0.21) earnings per share for the quarter. As a group, analysts forecast that Greenwich LifeSciences, Inc. will post -0.76 earnings per share for the current year.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were bought at an average cost of $19.08 per share, with a total value of $57,240.00. Following the purchase, the chief executive officer now directly owns 5,350,777 shares in the company, valued at $102,092,825.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have purchased 23,800 shares of company stock valued at $327,722. Corporate insiders own 52.86% of the company’s stock.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.